Tierarztl Prax Ausg K Kleintiere Heimtiere 2014; 42(06): 367-373
DOI: 10.15654/TPK-140165
Original Article
Schattauer GmbH

Breed related odds ratio and anatomic distribution of canine mast cell tumours in Austria

Retrospective study of cases in the years 2000–2010Rassenspezifische Odds Ratio and anatomische Verteilung von Mastzelltumoren beim HundRetrospektive Auswertung von Fällen in den Jahren 2000–2010
E. F. Leidinger
1   In Vitro Veterinary Diagnostic Laboratory, Vienna, Austria
K. Freeman
2   IDEXX Laboratories, Wetherby, UK
G. Kirtz
1   In Vitro Veterinary Diagnostic Laboratory, Vienna, Austria
E. H. Hooijberg
1   In Vitro Veterinary Diagnostic Laboratory, Vienna, Austria
K. Sick
3   Dr. Sick Veterinärhistologische Diagnostik, Feldkirchen/Kärnten, Austria
› Author Affiliations
Further Information

Publication History

Received: 19 February 2014

Accepted after revision: 06 May 2014

Publication Date:
08 January 2018 (online)


Objective: An increased risk of mast cell tumours (MCT) in certain breeds has been described repeatedly in the literature. The incidence of MCTs for registered breeds in Austria, an estimate of the risk by means of the odds ratios based on breed as well as the anatomic localisation of MCTs were examined. Material and methods: In the first part of the study, the ranking of breeds in Austria based on 147,802 dogs with known breed (including mixed breed) was determined, based on those dogs included in the laboratory data base from 2000 to 2010. In the second part of the study, 476 dogs were identified with MCTs and analysed by age, sex, Patnaik grade of MCT and breed distribution. The odds ratios with confidence intervals were calculated for all breeds with skin tumours. Results: The age distribution showed a peak in the age group from 6.1 to 8.0 years; 70% of MCTs were localised to the head and trunk. No significant difference was found based on gender. The evaluation of the odds ratios showed that only four of the 20 of the most popular in Austria breeds (Boxer, Bernese Mountain Dog, Golden Retriever, Spaniel) had an increased risk; on the other hand, some breeds which have not been previously identified in the literature were indicated to have a significantly increased risk for MCT (e.g., Dogo Argentino, Tibetan Spaniel, Pyrenean Mountain Dog, Beauceron, and Austrian Smooth-haired Hound). Conclusion and clinical relevance: Because disease risk may influence the popularity of some currently rare breeds, consultation with breeders and owners regarding the identification of the breeds newly identified in this study as an increased risk for development of mast cell tumours is indicated.


Gegenstand und Ziel: Ein erhöhtes Risiko für Mastzelltumoren bei bestimmten Hunderassen wurde in der Literatur mehrfach beschrieben. In der Studie wurde die Inzidenz von Mastzelltumoren sowie deren anatomische Lokalisation bei in Österreich registrierten Rassen untersucht und die Wahrscheinlichkeit des Auftretens dieser Neoplasie bei einzelnen Rassen anhand der Odds Ratio ermittelt. Material und Methoden: Im ersten Teil der Studie erfolgte eine Bestimmung der Popularitätsrangfolge von Hunderassen in Österreich anhand von 147.802 Hunden mit bekannter Rasse (inklusive Mischlinge), die im Studienzeitraum in die Labordatenbank eingetragen wurden. Im zweiten Teil der Studie wurden 476 Hunde mit Mastzelltumoren identifiziert und nach Alter, Geschlecht, Patnaik-Grad des Mastzelltumors und Rassenverteilung untersucht. Die Odds Ratio mit Konfidenzintervallen wurde für alle Rassen mit untersuchten Hauttumoren berechnet. Ergebnisse: Die Altersverteilung zeigte einen Gipfel in der Altersgruppe 6,1–8,0 Jahre; 70% der Mastzelltumoren waren am Kopf und Rumpf lokalisiert. Zwischen den Geschlechtern bestand kein signifikanter Unterschied. Nach Auswertung der Odds Ratio wiesen nur vier der 20 der in Österreich populärsten Hunderassen (Boxer, Berner Sennenhund, Golden Retriever, Spaniel) ein erhöhtes Risiko auf, während bei einigen in der Literatur bislang nicht erwähnten Rassen ein deutlich erhöhtes Risiko festzustellen war (z. B. Dogo Argentino, Tibetspaniel, Pyrenäenhund, Beauceron und Brandlbracke). Schlussfolgerung und klinische Relevanz: Da sich die Popularität von derzeit seltenen Rassen ändern kann, ist eine Beratung von Züchtern und Besitzern in Hinblick auf Rassen mit hohem Risiko für einen Mastzelltumor wichtig.

  • References

  • 1 American Kennel Club (AKC). http://www.akc.org/reg/dogreg_stats.cfm accessed 04/12/13..
  • 2 Brønden LB, Eriksen T, Kristensen AT. Mast cell tumours and other skin neoplasia in Danish dogs – data from the Danish Veterinary Cancer Registry. Acta Vet Scand 2010; 52: 1-6.
  • 3 O’Connor AM. Interpretation of odds and risk ratio. J Vet Intern Med 2013; 27: 600-603.
  • 4 Dobson JM, Samuel S, Milstein H, Rogers K, Wood JLN. Canine neoplasia in the UK: estimates of incidence rates from a population of insured dogs. J Small Animal Pract 2002; 43: 240-246.
  • 5 Dobson JM. Breed-predispositions to cancer in pedigree dogs. ISRN Vet. Sci. 2013 doi 10.1155/2013/941275. 23 pages..
  • 6 Egenvall A, Bonnet BN, Hedhammar Å, Olson P. Mortality in over 350,000 insured Swedish dogs from 1995–2000. II. Breed-specific age and survival patterns and relative risk for causes of death. Acta Vet Scand 2005; 46: 121-136.
  • 7 German Kennel Club (VDH [Verband für das Deutsche Hundewesen]). http://www.partner-hund.de/info-rat/hunderassen/beliebteste-hunderas- sen.html accessed 04/12/13..
  • 8 Grabarevic Z, Spoljar JB, Kurilj AG, Sostarić-Zuckermann IC, Artuković B, Hohsteter M, Beck A, Dzaja P, Strmecki NM. Mast cell tumors in dogs – Incidence and histopathological characterization. Col Antropol 2009; 33: 253-258.
  • 9 Hahn KA, Ogilvie GK, Rusk T, Devauchelle P, Leblanc A, Legendre A, Powers B, Leventhal PS, Kinet JP, Palmerini F, Dubreuil P, Moussy A, Hermine O. Masitinib is safe and effective for the treatment of canine mast cell tumors. J Vet Intern Med 2008; 22: 1301-1309.
  • 10 Hottendorf GH, Nielsen SW. Canine mastocytoma – a review of clinical aspects. JAVMA 1969; 154: 917-924.
  • 11 Kiupel M, Webster JD, Bailey KL, Best S, DeLay J, Detrisac CJ, Fitzgerald SD, Gamble D, Ginn PE, Goldschmidt MH, Hendrick MJ, Howerth EW, Janovitz EB, Langohr I, Lenz SD, Lipscomb TP, Miller MA, Misdorp W, Moroff S, Mullaney TP, Neyens I, O’Toole D, Ramos-Vara J, Scase TJ, Schulman FY, Sledge D, Smedley RC, Smith K, Snyder PW, Southorn E, Stedman NL, Steficek BA, Stromberg PC, Valli VE, Weisbrode SE, Yager J, Heller J, Miller R. Proposal of a 2-tier histologic grading system for canine cutaneous mast cell tumors to more accurately predict biological behavior.. Vet Pathol 2011; 48: 147-155.
  • 12 London CA, Malpas PB, Wood-Follis SL, Boucher JF, Rusk AW, Rosenberg MP, Henry CJ, Mitchener KL, Klein MK, Hintermeister JG, Bergman PJ, Couto GC, Mauldin GN, Michels GM. Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision. Clin Cancer Res 2009; 15: 3856-3865.
  • 13 Macy DW. Canine mast cell tumors. Vet Clin North Am: Small Anim Pract 1985; 15: 783-803.
  • 14 MacVean DW, Monlux AW, Anderson Jr PS, Silberg SL, Roszel JF. Frequency of canine and feline tumors in a defined population. Vet Pathol 1978; 15: 700-715.
  • 15 Miller DM. The occurrence of mast cell tumors in young Shar-Peis. J Vet Diagn Invest 1995; 07: 360-363.
  • 16 Misdorp W. Mast cells and canine mast cell tumours. A review. Vet Q 2004; 26: 156-169.
  • 17 Monteiro B, Boston S, Monteith G. Factors influencing complete tumor excision of mast cell tumors and soft tissue sarcomas: a retrospective study in 100 dogs. Can Vet J 2011; 52: 1209-1214.
  • 18 Murphy S, Sparkes AH, Blunden AS, Brearley MJ, Smith KC. Effects of stage and number of tumours on prognosis of dogs with cutaneous MCTs. Vet Rec 2006; 158: 287-291.
  • 19 Nielson SW, Cole CR. Canine mastocytoma – a report of one hundred cases. Am J Vet Res 1958; 19: 417-432.
  • 20 Patnaik AK, Ehler WJ, MacEwen EG. Canine cutaneous mast cell tumor: morphologic grading and survival time in 83 dogs. Vet Pathol 1984; 21: 469-474.
  • 21 Pakhrin B, Kang MS, Bae IH, Park MS, Jee H, You MH, Kim JH, Yoon BI, Choi YK, Kim DY. Retrospective study of canine cutaneous tumors in Korea. J Vet Sci 2007; 08: 229-236.
  • 22 Preziosi R, Sarli G, Paltrinieri M. Multivariate survival analysis of histological parameters and clinical presentation in canine cutaneous mast cell tumours. Vet Res Com 2007; 31: 287-296.
  • 23 Raskin RE, Meyer D. Atlas of Canine and Feline Cytology. 2nd edn.. Philadelphia: Saunders; 2009: 67-69.
  • 24 Riva F, Brizzola S, Stefanello D, Crema S, Turin L. A study of mutations in the c-kit gene of 32 dogs with mastocytoma. J Vet Diagn Invest 2005; 17: 385-388.
  • 25 Taney K, Smith MM. Resection of mast cell tumor of the lip in a dog. J Vet Dent 2009; 26: 28-34.
  • 26 Villamil JA, Henry CJ, Bryan JN, Ellersieck M, Schultz L, Tyler JW, Hahn AW. Identification of the most common cutaneous neoplasms in dogs and evaluation of breed and age distributions for selected neoplasms. JAVMA 2011; 239: 950-960.
  • 27 Welle MM, Bley CR, Howard J. Canine mast cell tumours: a review of the pathogenesis, clinical features, pathology and treatment. Vet Dermatol 2008; 19: 321-329.
  • 28 Yager JA, Wilcock BP. Color Atlas and Text of Surgical Pathology of the Dog and the Cat. Dermatopathology and Skin Tumours. London: Wolfe Publishing; 1994: 278-281.